We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes.
Antimicrobial Agents and Chemotherapy 2011 July
NXL104, a novel β-lactamase inhibitor, was tested at a constant concentration of 4 μg/ml in combination with ceftazidime (CAZ), with and without added metronidazole, against 396 β-lactamase-producing strains of anaerobic bacteria. MIC(50)/MIC(90) values for Bacteroides fragilis and the B. fragilis group were 8/16 and 64/>128 μg/ml, respectively. Although CAZ-NXL104 had limited activity against most anaerobic strains, in combination with metronidazole it shows potential for treating mixed infections involving resistant Enterobacteriaceae and anaerobes.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app